Search

A report from Poznan University of Medical Sciences in Poland discusses research on neurodegenerative diseases and the search for new drugs to combat them. The researchers synthesized bis-chalcone derivatives and evaluated their effects in biological tests and in silico analysis. The compounds showed antioxidant activity and inhibited enzymes associated with neurodegeneration. In addition, they had a positive effect on a mouse hippocampal neuronal cell line. The results obtained in in silico models were consistent with in vitro experiments. [Extracted from the article]

Researchers from the Department of Chemistry in Gujarat, India have synthesized and characterized a series of novel fluorinated diphenylamine chalcone derivatives. These compounds were tested for their antibacterial, antifungal, and antimalarial activities. The results showed that compounds A1 and A2 exhibited significant antibacterial and antifungal properties, with high anti-Plasmodium falciparum activity. Molecular docking investigations revealed that these compounds bind to the active site of falcilysin, and molecular dynamic simulations confirmed their stability and interaction with P. falciparum. Additionally, compounds A1 and A4 demonstrated cytotoxicity against HeLa cells. The researchers concluded that compounds A1 and A2 have the potential to be developed into novel drug-like molecules with multiple therapeutic properties. [Extracted from the article]

The article examines the use of bupropion in treating patients with comorbid Post-Traumatic Stress Disorder (PTSD) and Methamphetamine Use Disorder (MUD). Topics include the positive outcomes of bupropion in reducing PTSD symptoms and relapse rates compared to traditional serotonergic agents, as well as lower hospital utilization. The study suggests that bupropion may be a beneficial early treatment option for individuals with both PTSD and MUD.

The article focuses on a study investigating how dialyl-sulfide and trans-chalcone can prevent breast cancer by targeting specific proteins and pathways. Topics include the role of SULT1E1 protein in breast cancer progression, the effects of oxidative stress on HIF1a and MMPs, and the potential therapeutic benefits of using dialyl-sulfide and chalcone in cancer treatment.

The article details a study from the University of Florida on the risk of injurious falls among older adults receiving first-line treatments for depression. Topics discussed include the comparative risk of falls associated with different antidepressants, the use of psychotherapy versus medication, and the implications for prescribing practices in older adults.

The article discusses a patent application for dosage forms of enantiomerically enriched or pure (S)-bupropion, aimed at providing equivalent therapeutic effects to racemic bupropion with potentially lower doses. Topics discussed include the background of bupropion's use, specific dosage formulations, and methods of administration for achieving desired pharmacokinetic profiles and therapeutic outcomes.

A recent study conducted by researchers at Macau University of Science and Technology explored the potential anticancer effects of a chalcone derivative called SBD-2 on colorectal cancer (CRC) cells. The study found that SBD-2 inhibited the proliferation of CRC cells, induced apoptosis, and arrested the cell cycle. These effects were attributed to the inhibition of the Akt pathway, which led to the suppression of anti-apoptotic protein Bcl-2 and cell cycle regulator Cyclin B1. The findings suggest that SBD-2 could be developed as a new agent for CRC treatment. [Extracted from the article]

A recent report from researchers at BITS discusses the role of phenol soluble modulin a1 (PSM a1) in Staphylococcus aureus and its impact on antibiotic resistance. PSM a1 is a peptide involved in the formation of an extracellular fibril structure with amyloid-like properties, which makes the staphylococcal biofilm resistant to antibiotics. The researchers conducted biophysical and computational assays to study the inhibitory effect of a prenylated chalcone called Isobavachalcone (IBC) on the amyloid fibrillation of PSM a1. Their findings suggest that IBC disrupts the amyloid transformation of PSM a1, providing insights for the development of non-toxic therapeutic agents targeting antibiotic-resistant staphylococcal biofilm assembly. [Extracted from the article]

A recent study conducted at Pondicherry University in India explored the potential of 26 hybrid compounds containing sulfonamide, chalcone, and nitro group scaffolds as anti-malarial agents. The compounds were tested against the human malarial parasite Plasmodium falciparum, and two compounds showed significant inhibitory activity. These compounds did not exhibit toxic effects on host red blood cells or human and murine cells. The study suggests that the hybrid scaffold, 4-nitrobenzenesulfonamide chalcones, has potential as an anti-plasmodial agent. [Extracted from the article]

Researchers at the Department of Applied Sciences have published a study on the potential of chalcone derivatives as pharmaceutical agents. The researchers synthesized a series of new compounds and investigated their properties using spectroscopic techniques. In-silico investigations were also conducted to evaluate the drug-likeliness properties and ADMET characteristics of the compounds. The study found that certain compounds showed promising antibacterial sensitivity. Overall, the research provides valuable insights into the development of novel compounds with diverse pharmacological activities and enhanced drug-like properties. [Extracted from the article]

A recent report from Texas Technical University discusses the findings of a study on the drug bupropion, which is used as an antidepressant and smoking cessation aid. The research reveals that bupropion inhibits certain ion channels in the brain, which may contribute to its effects. The study identifies specific binding sites for bupropion within these ion channels and explores the impact of amino acid substitutions on the drug's inhibitory effects. The research suggests that these findings could help improve our understanding of how bupropion works and potentially lead to the development of more effective treatments. [Extracted from the article]

The article reports on a patent (USPTO 12048769) issued to Nalpropion Pharmaceuticals LLC for methods related to administering weight loss medications, specifically aimed at minimizing side effects during treatment. It states that the patented method involves gradually increasing the dosage of a combination of bupropion and naltrexone to improve patient compliance and comfort while effectively treating obesity and related conditions.

New research from the University of Pavol Jozef Safarik in Slovakia has investigated the effects of a chalcone derivative called 1C on ovarian cancer cell lines. The study found that 1C suppressed cell viability, induced cell cycle arrest, and triggered apoptosis in both sensitive and resistant ovarian cancer cells. These effects were associated with the generation of reactive oxygen species (ROS) and the modulation of various signaling pathways. The research suggests that the antiproliferative activity of 1C is partially mediated by the modulation of Nrf2 levels. The study highlights the potential of chalcone derivatives as a treatment for ovarian cancer. [Extracted from the article]

Researchers at Princess Nourah bint Abdulrahman University in Riyadh, Saudi Arabia have conducted a study on Helicobacter pylori, a bacterium that causes peptic ulcer disease (PUD). The study aimed to develop novel anti-ulcer compounds by combining different pharmacophores. The researchers synthesized chalcone derivatives and characterized them using spectroscopic techniques. They also performed DFT calculations and molecular docking to evaluate the compounds' properties and their interaction with H. pylori enzymes. The study concluded that these chalcones have potential as therapeutic candidates for PUD due to their anti-inflammatory, antimicrobial, and anti-adhesion properties. [Extracted from the article]

Researchers from the University of Pecs in Hungary have conducted a study on the reactivity of chalcones, a type of compound, with cellular thiols. They investigated the kinetics and diastereoselectivity of the addition of reduced glutathione and N-acetylcysteine to cyclic chalcone analogs at different pH values. The compounds showed in vitro cancer cell cytotoxicity, and the reactions were evaluated using high-pressure liquid chromatography with UV detection and high-pressure liquid chromatography-mass spectrometry. The researchers concluded that the observed reactivities did not directly correlate with the difference in cytotoxicity. The study was published in the International Journal of Molecular Sciences. [Extracted from the article]

Researchers from Andhra University in Visakhapatnam, India have synthesized and evaluated the cytotoxicity of various chalcones and dihydropyrazole derivatives as potential anticancer agents for breast cancer treatment. The compounds showed promising activity against triple-negative breast cancer cell lines, with two compounds exhibiting IC50 values of 4.02 μM and 3.35 μM. In addition, in silico pharmacokinetic and toxicity studies indicated favorable bioavailability of these derivatives. This research has been peer-reviewed and provides valuable insights for drug discovery in breast cancer therapy. [Extracted from the article]

Researchers at the University Hospital Centre Sisters of Charity in Zagreb, Croatia have conducted a narrative review on the effectiveness of bupropion in cigarette smoking cessation. Bupropion, originally developed as an antidepressant, has shown promising results in helping patients quit smoking. It is considered a potential cost-effective alternative to nicotine replacement therapy. The drug primarily acts by inhibiting dopamine reuptake in neuronal synapses, but other effects may also contribute to its efficacy. This research provides valuable insights for individuals seeking smoking cessation treatments. [Extracted from the article]

A recent study conducted at Washington State University has developed a phenotyping cocktail for dogs to evaluate the activities of specific hepatic enzymes. The study aimed to determine if alternative sampling methods such as saliva and urine could be used instead of multiple blood sampling. The researchers found that the cocktail was well tolerated and that single time point plasma samples at 4 hours post-dose strongly correlated with the corresponding area under the plasma concentration-versus-time curve ratios. The study concluded that the cocktail has potential as a useful tool in dogs to detect drug-drug interactions and aid in individualized dose selection. [Extracted from the article]

A report from Mumbai, India discusses the synthesis and evaluation of a novel class of chalcones as potential anticancer agents. The compounds were synthesized using a specific chemical reaction and characterized using various techniques. In vitro testing showed that several of the synthesized compounds exhibited anticancer activity and antioxidant activity. Molecular docking simulations also indicated that these compounds had a high binding energy to a specific enzyme. Additionally, the compounds demonstrated good oral bioavailability properties. This research provides valuable insights into the design and synthesis of potential anticancer agents. [Extracted from the article]

A preprint abstract from biorxiv.org discusses a potential alternative therapeutic approach to trastuzumab, a monoclonal antibody drug used to target HER2 overexpression in various solid tumors. The study focuses on targeting the protein-protein interaction between ELF3 and MED23 as a potential intervention for HER2-overexpressing cancers. The researchers synthesized 26 compounds and found that compound 10 effectively disrupted the ELF3-MED23 interaction, leading to a reduction in HER2 levels and downstream signals in gastric cancer cells. Compound 10 also demonstrated anticancer activity in trastuzumab-refractory cases, suggesting its potential as a therapeutic option for trastuzumab-resistant gastric cancers. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

A recent study conducted by researchers at the Pontifical Catholic University of Valparaiso has synthesized a novel series of antitumor hybrids using 1,4-benzohydroquinone and chalcone, furane, or pyrazoline scaffolds. These hybrids were found to have potential antitumor activity, with cytotoxic effects observed on breast adenocarcinoma and colorectal carcinoma cells. The incorporation of furan and pyrazoline groups significantly enhanced the antiproliferative properties of the compounds. Molecular docking studies also suggested that these derivatives could be promising chemotherapeutic agents targeting kinase pathways. The study concludes that some of these compounds hold promise as potential candidates for preclinical assays. [Extracted from the article]

A recent study conducted by researchers at the University of New South Wales Sydney examined the use of smoking cessation pharmacotherapies during pregnancy. The study found that there is a lack of evidence regarding the safety of these medications during pregnancy, particularly in relation to the risk of congenital malformations. Current guidelines advise against the use of varenicline and bupropion, and recommend caution with nicotine replacement therapy. The study also found that the prevalence of varenicline and bupropion use during pregnancy was low, while nicotine replacement therapy was more commonly used. Further research is needed to determine the potential risks associated with these medications. [Extracted from the article]

A new report from the Department of Health discusses the synthesis and characterization of new 5-fluoroisatin-chalcone conjugates with expected antimicrobial activity. The research highlights the importance of developing new antimicrobial agents due to the increasing resistance of pathogenic microorganisms. The compounds synthesized in this study showed potential as antibacterial agents against E. coli and S. aureus, as well as antifungal agents against C. albicans. The most active compound was identified as compound 5e, while compound 5g exhibited the least activity. [Extracted from the article]

Researchers at Lahore Garrison University have conducted a study on chalcones, a class of compounds known for their broad-spectrum biological activities, to evaluate their potential as antibacterial and antibiofilm agents. The synthesized chalcones showed promising results, with compounds 5a and 5d exhibiting potent antibacterial activity against multidrug-resistant bacteria. Additionally, these compounds demonstrated significant biofilm inhibition efficacy. Molecular docking studies further supported the potential of chalcones, particularly compound 5a, as promising candidates for the development of new antimicrobial agents targeting drug-resistant microbes and biofilm formation. This research provides valuable insights into the search for novel antimicrobial agents to combat drug resistance. [Extracted from the article]

A study conducted at Duke University in Durham, North Carolina, explored the pharmacogenetic influence on the steady-state disposition of bupropion, an antidepressant and smoking cessation agent. The research found that genetic variations in certain enzymes, specifically CYP2B6, affected the metabolism and bioactivation of bupropion, potentially impacting its therapeutic outcomes. The study highlights the importance of considering genetic factors when prescribing bupropion and suggests that personalized medicine approaches may improve treatment efficacy. This research was supported by the US Food & Drug Administration and other institutions. [Extracted from the article]

A recent report from the School of Advanced Sciences in Tamil Nadu, India discusses the synthesis of 1,2,3-trisubstituted triazoles through the cycloaddition of different chalcones with azides. The researchers used Cu(II) complexes as catalysts and achieved moderate to excellent yields. The synthesized triazole derivatives showed potential cytotoxic characteristics against MCF-7 cancer cell lines, with some compounds demonstrating notable IC50 values. The photophysical properties of the products were found to depend on the nature of the substituents. This research provides valuable insights into the green synthesis of triazole derivatives and their potential applications in cancer treatment. [Extracted from the article]

A recent study published in the Annals of Internal Medicine compared the weight gain associated with eight different first-line antidepressant medications. The study found that users of bupropion were 15-20% less likely to gain a clinically significant amount of weight compared to users of sertraline, the most commonly prescribed medication. Weight gain is a common side effect of antidepressants and can have long-term effects on metabolic health. The study provides important real-world evidence for patients and clinicians to consider when choosing an antidepressant. [Extracted from the article]

A recent study conducted at Mody University of Science and Technology in Rajasthan, India, focused on the synthesis and characterization of new compounds derived from symmetrical chalcones. The researchers used various spectroscopic techniques to describe the newly synthesized compounds and evaluated their antibacterial properties against Bacillus subtilis and Escherichia coli. Molecular docking and in silico analysis were also performed to determine the compounds' binding affinity and drug-likeness properties. The study found that the synthesized molecules showed promising antibacterial activity and exhibited favorable drug-like properties. [Extracted from the article]

A recent study conducted by the University of California Los Angeles (UCLA) examined the effects of extended-release injectable naltrexone and extended-release oral bupropion on methamphetamine use. The study found that participants who received the combination treatment showed a significant increase in the probability of testing negative for methamphetamine compared to those who received a placebo. The research suggests that continued treatment with naltrexone and bupropion beyond 6 weeks can lead to further reductions in methamphetamine use. This study provides valuable insights for individuals with methamphetamine use disorder seeking effective treatment options. [Extracted from the article]

A recent report discusses research on antipsychotics and their potential adverse cardiovascular effects. The study aimed to validate predictors of adverse cardiovascular events (ACVE) in patients who presented to the emergency department after a bupropion overdose. The researchers found that low initial serum bicarbonate levels, prolonged QTc interval, and elevated serum lactate were independent predictors of ACVE. These findings suggest the need for further investigation into the relationship between bupropion overdose and cardiovascular events. [Extracted from the article]

New breast cancer research conducted in Warangal, India has focused on the synthesis of novel pyrrole-chromone based chalcones and their potential anti-breast cancer activity. The researchers found that one particular compound, synthesized with a 30% NaOH solution at a temperature of 60-65 °C for twelve hours, yielded positive results. In silico studies showed that these compounds exhibited strong binding affinity to proteins associated with breast cancer, indicating their potential as anti-breast cancer drugs. Further research is needed to explore the development of these compounds as potential treatments. [Extracted from the article]

Researchers at Mustansiriyah University in Baghdad, Iraq have conducted a study on new 3-furan-1-thiophene-based chalcones as antibacterial and anticancer agents. The compounds were synthesized, characterized, and evaluated for their pharmacological properties. The results showed that the chalcones exhibited antibacterial activity against both Gram-positive and Gram-negative bacterial species. Additionally, one of the compounds demonstrated potent anticancer activity against breast cancer cells. Molecular docking studies supported the in vitro findings, suggesting that these chalcones could be potential candidates for the development of novel antibacterial and anticancer drugs. [Extracted from the article]

Researchers at Northern Border University in Arar, Saudi Arabia have conducted a study on the synthesis and performance of natural chalcone dye-functionalized magnetite nanoparticles (Magn_NCD NPs) for the removal of methylene blue (MB) and their antibacterial activity. The researchers achieved size control of the nanoparticles by varying the pH of the reaction medium. The smallest nanoparticles (Magn_NCD5) showed the highest removal efficiency of MB, with the removal efficiency increasing with an increase in pH. The nanoparticles also exhibited good reusability and demonstrated antimicrobial activity against gram-negative and gram-positive bacteria. [Extracted from the article]

A patent has been issued for compositions and methods aimed at reducing major adverse cardiovascular events (MACE). Cardiovascular disease is the leading cause of death worldwide, and there is a need for new treatments. The patent describes the use of naltrexone and bupropion, or their salts, to reduce the risk of MACE in patients at an increased risk. The method involves administering these drugs to the patient over a period of at least one week. The patent also mentions the exclusion of patients with diabetes and other medical conditions from anti-obesity drug clinical studies, highlighting the need for effective treatments in these populations. [Extracted from the article]

A research study conducted at the Shanghai Institute of Technology in China focused on designing and synthesizing novel chalcone amide alpha-glucosidase inhibitors for the treatment of Type II diabetes. The researchers used virtual screening and molecular dynamics simulation to create a series of compounds (L1-L10) and found that compound L4 exhibited the best inhibitory activity against alpha-glucosidase. The study suggests that compound L4 has the potential to be a promising candidate for further investigation as an anti-Type II diabetes treatment. The research has been peer-reviewed and published in the journal Future Medicinal Chemistry. [Extracted from the article]

A recent research study conducted at Manipal Academy of Higher Education in Manipal, India, focused on the development of drug molecules with high therapeutic activity and low toxicity. The study specifically examined naphthyl-based chalcone derivatives, which have simple structures and a wide range of pharmacological effects. The research provided an overview of the biologically active molecules based on these derivatives, including their structure-activity relationships, action mechanisms, and potential therapeutic applications. The study found that the presence of certain chemical groups enhanced the anticancer and antibacterial activities of these derivatives. However, further research is needed to explore their pharmacological activities in other areas. [Extracted from the article]

Researchers from Maharaja Ranjit Singh Punjab Technical University in Bathinda, India have synthesized a series of isatin-chalcone linked triazoles and evaluated their cytotoxicity against various cancer cell lines. The most potent compound showed approximately 2.5 times greater activity compared to reference compounds against ovarian cancer cell lines. The findings were supported by caspase-mediated apoptosis and molecular docking analyses, which revealed the compound's strong interaction with EGFR. Overall, the results highlight the anti-proliferative potential of the synthesized hybrids, particularly compound 5b, in suppressing cancer cell growth. The research was financially supported by UGC (NFSC) and has been peer-reviewed. [Extracted from the article]

A case report and review of literature from Creighton University School of Medicine discusses a middle-aged male patient who presented with persistent left-sided chest pain. The patient's medical history included tobacco use and depression, and his vital signs showed mild hypertension. After ruling out life-threatening conditions, the patient's home medications were reviewed, and it was discovered that his chest pain was likely caused by bupropion, a medication he was taking. Discontinuing the medication resulted in the resolution of his symptoms. The study concludes that patients taking bupropion may experience atypical chest pain, and discontinuation of the medication may alleviate symptoms. [Extracted from the article]